Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Gross Margin (2016 - 2019)

Cardiff Oncology (CRDF) has disclosed Gross Margin for 7 consecutive years, with 100.0% as the latest value for Q4 2019.

  • Quarterly Gross Margin changed 0.0% to 100.0% in Q4 2019 from the year-ago period, while the trailing twelve-month figure was 100.0% through Dec 2019, up 18145.0% year-over-year, with the annual reading at 100.0% for FY2019, 15792.0% up from the prior year.
  • Gross Margin hit 100.0% in Q4 2019 for Cardiff Oncology, roughly flat from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2018 to a low of 7512.13% in Q4 2015.
  • Historically, Gross Margin has averaged 535.35% across 5 years, with a median of 132.54% in 2017.
  • Biggest five-year swings in Gross Margin: plummeted -758456bps in 2015 and later skyrocketed 674858bps in 2016.
  • Year by year, Gross Margin stood at 7512.13% in 2015, then surged by 90bps to 763.56% in 2016, then skyrocketed by 86bps to 107.35% in 2017, then surged by 193bps to 100.0% in 2018, then changed by 0bps to 100.0% in 2019.
  • Business Quant data shows Gross Margin for CRDF at 100.0% in Q4 2019, 100.0% in Q3 2019, and 100.0% in Q2 2019.